Antidote Therapeutics
UEI: KNPKVDXDCNL9
• CAGE: 70JF3
Overview
Awardee Type
Parent
Company Description
Antidote Therapeutics, a science-driven biopharmaceutical company focused on developing novel nicotine-blocking therapies to treat diseases caused or worsened by nicotine.
Name
Antidote Therapeutics
Website
Headquarters
Sykesville, MD
United States
United States
Most Recent Award
May 1, 2023
Calculating
Federal grant recipient
ANTIDOTE THERAPEUTICS INC
(UEI KNPKVDXDCNL9, CAGE 70JF3)
is headquartered in Sykesville MD.
The corporation
was founded in May 2013 and
federally registered in
November 2013.
Federal Award Analysis
Antidote Therapeutics federal award history
$-
Contracts
$-
Subcontracts
$-
Grants
$-
Subgrants
$-
Total
No Results
Calculating
Calculating
No Results
Calculating
Calculating
No Results
Calculating
Calculating
| Year | Contracts | Subcontracts | Grants | Subgrants |
|---|
No Results
Calculating
Calculating
No Results
Calculating
Calculating
Federal Registration and Certifications
Legal Name
ANTIDOTE THERAPEUTICS INC
UEI
KNPKVDXDCNL9
CAGE Code
70JF3
Primary NAICS
None Reported
SBA Certifications
None
Self Certifications
None
Entity Structure
Corporate Entity (Not Tax Exempt)
Purpose of Registration
Federal Assistance Awards
Date Founded
May 7, 2013
Initial Registration
Nov. 15, 2013
Last Registration
May 6, 2024
Registration Activation
May 3, 2024
Registration Expiration
May 1, 2025
Fiscal Year End
December 31
Reported Entity Types
For Profit Organization
State of Incorporation
DE
Country of Incorporation
USA
Employees
Not Available
Reported NAICS
None Reported
Accepts Credit Cards
No